Cameron D. Thomas, Pharm.D., a postdoctoral fellow in the department of pharmacotherapy and translational research, was one of three postdocs selected to present his research project at the American College of Clinical Pharmacy, or ACCP, Annual Meeting, Oct. 29-30.
Thomas presented his postdoctoral research project titled, “Cardiovascular outcomes according to clinical presentation with CYP2C19-guided antiplatelet therapy in patients undergoing PCI: a multi-site investigation in real-world settings,” as part of the inaugural ACCP Research Fellowship Platform Session.
The research project aimed to determine the impact of CYP2C19 genotype-guided antiplatelet therapy among patients undergoing percutaneous coronary intervention, comparing patients who had acute coronary syndrome, or ACS, with those who did not. “We found that ACS patients especially benefit from CYP2C19-guided antiplatelet therapy selection and that among patients without a CYP2C19 loss-of-function allele, clopidogrel was as effective as alternative therapy after ACS,” Thomas said.